High-virulence Helicobacter pylori strains and smoking increase the risk of gastric precancerous lesions. However, its association with specific types of intestinal metaplasia has been poorly studied. We aimed to quantify the association between different types of intestinal metaplasia (complete, incomplete, and mixed) and these two risk factors. Male volunteers (n = 227) underwent an upper digestive endoscopy and completed symptoms and lifestyle questionnaires. A histologic diagnosis was assigned based on the lesions found in any of the biopsy specimens (antrum, body, or incisura). H. pylori vacA and cagA were directly genotyped by multiplex PCR and reverse hybridization. Each participant's smoking status at the time of endoscopy was assessed. Logistic and multinomial logistic regression models were fitted (including H. pylori virulence, smoking, age, and education as independent variables) using normal/chronic nonatrophic gastritis as the reference category. Compared with never smokers infected with low-virulence strains, the risk of intestinal metaplasia was increased in subjects infected with high-virulence strains [odds ratio (OR), 5.74; 95% confidence interval (95% CI), 1.68-19.63] and in ever smokers (OR, 3.54; 95% CI, 1.30-9.61). In ever smokers infected with high-virulence H. pylori strains, the risk of intestinal metaplasia was further increased (OR, 8.61; 95% CI, 3.07-24.17). Infection with high-virulence strains significantly increased the risk of incomplete (OR, 9.81; 95% CI, 2.39-40.31) and mixed (OR, 3.28; 95% CI, 1.51-7.14) intestinal metaplasia. Complete (OR, 2.82; 95% CI, 1.01-7.88) and mixed (OR, 2.97; 95% CI, 1.12-7.84) intestinal metaplasia were more frequent among ever smokers. High-virulence H. pylori strains and smoking are differentially associated with the complete and incomplete types of intestinal metaplasia, suggesting divergent pathways in gastric carcinogenesis. (Cancer Epidemiol Biomarkers Prev 2007;16(2):322–6)

It is widely accepted that “intestinal” type gastric carcinomas are preceded by atrophic gastritis, intestinal metaplasia, and dysplasia, following a set of sequential steps (1) amenable to modulation by environmental exposures. The association between specific Helicobacter pylori genotypes (cagA+, vacA s1, and vacA m1) and each of the steps that precede gastric carcinoma has been described (2-8). In addition, several studies addressed the association between different lifestyles and the occurrence of precancerous gastric lesions (9, 10), smoking being the most extensively studied and the one that more strongly increases the risk of intestinal metaplasia and intestinal metaplasia progression (10-18).

Histopathologic and histochemical studies allowed the identification of two main types of intestinal metaplasia: complete and incomplete. Their patterns of mucin expression favor the hypothesis of two alternative pathways for the metaplastic changes (19) rather than a single pathway based on successive steps of phenotypic modification of the gastric mucosa (1). The evaluation of specific risk factors for these end points has not been done before and may clarify the gastric carcinogenesis pathways and the role of environmental exposures in the etiology of cancer.

We therefore quantified the association between different types of intestinal metaplasia (complete, incomplete, and mixed) and infection with high-virulence H. pylori strains (simultaneously cagA+ and vacA s1/m1) and smoking.

Workers from the Viana do Castelo shipyard, north of Portugal, were invited to participate in a gastric pathology survey in 1998. Four hundred sixty (435 men and 25 women), nearly 40% of all the workers, volunteered to the study and completed a physician-administered questionnaire on digestive symptoms and had a blood sample drawn. An upper digestive endoscopy was done to 354 participants presenting dyspeptic symptoms or serum immunoglobulin G antibodies to H. pylori.

Biopsy specimens (one from corpus, one from antrum, and two from incisura angularis) were taken from each subject. The histologic diagnosis was based on the most severe lesion, following this descending order: intestinal metaplasia, chronic atrophic gastritis, and chronic nonatrophic gastritis. According to mucin markers (19), subjects were further classified as having complete intestinal metaplasia, incomplete intestinal metaplasia, or mixed intestinal metaplasia (if features of both complete and incomplete types were observed in the same biopsy or in different regions of the stomach). No cases of cancer or dysplasia were observed.

H. pylori cagA and vacA (s and m) genotypes were directly determined in the gastric biopsy specimen from the greater curvature of the antrum by multiplex PCR and reverse hybridization as previously described (20). Each subject was classified as infected with high-virulence (simultaneously cagA+ and vacA s1/m1, vacA s1/m2, or vacA s2/m1) or low-virulence strains (otherwise). Subjects simultaneously infected with vacA s1 and s2 strains or vacA m1 and m2 strains were considered as infected with high-virulence strains.

All participants were asked to fill out an additional self-administered questionnaire that included life-course information on smoking habits and alcohol consumption. Each subject was classified as never, former smoker (for ≥6 months), and current smoker (of any amount of cigarettes) at the time of the endoscopy. For current and former smokers, the lifetime consumption in pack-years was computed by multiplying the number of years that each subject has smoked by the average daily tobacco consumption expressed in number of packs (1 pack = 20 cigarettes). Additionally, smoking habits were dichotomized to never and ever, the latter including current and former smokers. For alcohol drinking (wine, beer, hard liquor, all alcoholic beverages), the participants were categorized according to the frequency of consumption at the time of the endoscopy: up to 1 drink per week, between 2 and 6, and ≥7 drinks per week.

Given the small number of women in the sample, we only present data for male participants. Only 11 subjects presented chronic atrophic gastritis as the severest lesion and were excluded from the analyses because the small number of subjects with these conditions does not allow the assessment of its specific risk factors. After these exclusions, complete information was available for 227 infected subjects, except for tobacco consumption in pack-years (n = 217) and for drinking habits (n = 213). The median age of the subjects in the final sample was 43.3 years (range, 25-59 years). Fifty-seven (25.1%) subjects had ≤4 education years, 128 (56.4%) had 5 to 9 years, and 42 (18.5%) studied for ≥10 years.

Among subjects undergoing endoscopy, there were no significant differences between those for whom we had complete information and those we had not, concerning median age (43.3 versus 44.4, P = 0.758), dyspeptic symptoms (34.4% versus 33.3%, P = 0.835), and infection with H. pylori determined by serology (97.4% versus 95.5%, P = 0.327). Participants not providing complete information were significantly less educated (41.0% versus 25.1% having ≤4 education years, P < 0.001).

Unconditional logistic (intestinal metaplasia defined as present or absent) and multinomial logistic regression (intestinal metaplasia defined as complete, incomplete or mixed) models were fitted using STATA, version 9.2, to compute crude and adjusted odds ratios (OR), respectively, for intestinal metaplasia and intestinal metaplasia types. Subjects with normal stomach or chronic nonatrophic gastritis were the reference category in all analyses. The existence of an interaction between H. pylori virulence and smoking status was assessed both in the additive and multiplicative scales, respectively, computing the interaction contrast ratio (21) and including an interaction term (smoking × H. pylori virulence) in the logistic regression model.

Eighty (35.2%) subjects presented intestinal metaplasia, complete (n = 30; 13.2%), incomplete (n = 13; 5.7%), or mixed (n = 37; 16.3%). The remaining 147 (64.8%) had normal stomach or chronic nonatrophic gastritis.

One hundred thirty-one (57.7%) subjects were infected with cagA+ strains. The infecting strains were vacA s1 in 109 (48.0%) participants, vacA s2 in 80 (35.2%), and multiple vacA s genotypes in 38 (16.7%) subjects. Eighty-three (36.6%) individuals were infected with vacA m1, 104 (45.8%) with vacA m2, and 40 (17.6%) with both vacA m genotypes.

The risk of intestinal metaplasia was significantly higher in subjects older than 50 years compared with those under 40 years [OR, 4.01; 95% confidence interval (95% CI), 1.48-10.84]. Infection with cagA+ (OR, 4.70; 95% CI, 2.46-9.01), vacA s1 (OR, 7.18; 95% CI, 3.35-15.36) or vacA m1 (OR, 5.93; 95% CI, 3.02-11.62) was significantly associated with intestinal metaplasia. Both current smokers (OR, 3.19; 95% CI, 1.51-6.73) and ever smokers with a lifetime consumption of ≥20 pack-years (OR, 2.65; 95% CI, 1.26-5.58) also presented a significantly increased risk of intestinal metaplasia when compared with never smokers. No statistically significant association was observed between the occurrence of intestinal metaplasia and consumption of alcoholic beverages (Table 1).

Table 1.

Association between intestinal metaplasia and socio-demographic, H. pylori virulence, and lifestyle variables (logistic regression analysis)

Normal stomach/chronic nonatrophic gastritis
Intestinal metaplasia
n (%)n (%)Crude OR (95% CI)Adjusted OR (95% CI)*
Age (y)     
    <40 61 (41.5) 22 (27.5) 1 [reference] 1 [reference] 
    40-50 76 (51.7) 44 (55.0) 1.60 (0.87-2.96) 1.66 (0.88-3.14) 
    >50 10 (6.8) 14 (17.5) 3.88 (1.51-10.00) 4.01 (1.48-10.84) 
Education (y)     
    ≤4 35 (23.8) 22 (27.5) 1 [reference] 1 [reference] 
    5-9 81 (55.1) 47 (58.8) 0.92 (0.48-1.76) 1.24 (0.62-2.49) 
    ≥10 31 (21.1) 11 (13.7) 0.56 (0.24-1.35) 0.83 (0.33-2.09) 
cagA genotype     
    Negative 79 (53.7) 17 (21.2) 1 [reference] 1 [reference] 
    Positive 68 (46.3) 63 (78.8) 4.30 (2.30-8.05) 4.70 (2.46-9.01) 
vacA s genotype     
    s2 68 (46.2) 12 (15.0) 1 [reference] 1 [reference] 
    s1 52 (35.4) 57 (71.2) 6.21 (3.02-12.76) 7.18 (3.35-15.36) 
    s1/s2 27 (18.4) 11 (13.8) 2.31 (0.91-5.86) 2.50 (0.96-6.54) 
vacA m genotype     
    m2 83 (56.5) 21 (26.2) 1 [reference] 1 [reference] 
    m1 34 (23.1) 49 (61.3) 5.70 (2.98-10.90) 5.93 (3.02-11.62) 
    m1/m2 30 (20.4) 10 (12.5) 1.32 (0.56-3.12) 1.16 (0.48-2.80) 
Smoking status     
    Never smoker 52 (35.4) 16 (20.0) 1 [reference] 1 [reference] 
    Former smoker 50 (34.0) 28 (35.0) 1.82 (0.88-3.76) 1.78 (0.84-3.76) 
    Current smoker 45 (30.6) 36 (45.0) 2.60 (1.28-5.29) 3.19 (1.51-6.73) 
Tobacco use (pack-years)§     
    Never smoker 52 (36.6) 16 (21.3) 1 [reference] 1 [reference] 
    <20 50 (35.2) 27 (36.0) 1.76 (0.84-3.64) 2.02 (0.95-4.33) 
    ≥20 40 (28.2) 32 (42.7) 2.60 (1.25-5.38) 2.65 (1.26-5.58) 
Alcohol consumption (drinks/wk)     
    ≤1 13 (9.3) 5 (6.8) 1 [reference] 1 [reference] 
    2-6 25 (18.0) 10 (13.5) 1.04 (0.29-3.69) 1.09 (0.30-3.95) 
    ≥7 101 (72.7) 59 (79.7) 1.52 (0.52-4.47) 1.35 (0.45-4.06) 
Wine consumption (drinks/wk)**     
    ≤1 14 (10.3) 6 (8.3) 1 [reference] 1 [reference]†† 
    2-6 27 (19.8) 11 (15.3) 0.95 (0.29-3.11) 0.83 (0.22-3.16) 
    ≥7 95 (69.9) 55 (76.4) 1.35 (0.49-3.72) 1.03 (0.30-3.47) 
Beer consumption (drinks/wk)‡‡     
    ≤1 53 (40.2) 28 (38.9) 1 [reference] 1 [reference]†† 
    2-6 51 (38.6) 34 (47.2) 1.26 (0.67-2.37) 1.56 (0.75-3.25) 
    ≥7 28 (21.2) 10 (13.9) 0.68 (0.29-1.59) 0.64 (0.23-1.78) 
Hard liquor consumption (drinks/wk)§§     
    ≤1 79 (59.0) 48 (64.0) 1 [reference] 1 [reference]†† 
    2-6 50 (37.3) 22 (29.3) 0.72 (0.39-1.34) 0.63 (0.30-1.30) 
    ≥7 5 (3.7) 5 (6.7) 1.64 (0.45-5.98) 2.66 (0.57-12.33) 
Normal stomach/chronic nonatrophic gastritis
Intestinal metaplasia
n (%)n (%)Crude OR (95% CI)Adjusted OR (95% CI)*
Age (y)     
    <40 61 (41.5) 22 (27.5) 1 [reference] 1 [reference] 
    40-50 76 (51.7) 44 (55.0) 1.60 (0.87-2.96) 1.66 (0.88-3.14) 
    >50 10 (6.8) 14 (17.5) 3.88 (1.51-10.00) 4.01 (1.48-10.84) 
Education (y)     
    ≤4 35 (23.8) 22 (27.5) 1 [reference] 1 [reference] 
    5-9 81 (55.1) 47 (58.8) 0.92 (0.48-1.76) 1.24 (0.62-2.49) 
    ≥10 31 (21.1) 11 (13.7) 0.56 (0.24-1.35) 0.83 (0.33-2.09) 
cagA genotype     
    Negative 79 (53.7) 17 (21.2) 1 [reference] 1 [reference] 
    Positive 68 (46.3) 63 (78.8) 4.30 (2.30-8.05) 4.70 (2.46-9.01) 
vacA s genotype     
    s2 68 (46.2) 12 (15.0) 1 [reference] 1 [reference] 
    s1 52 (35.4) 57 (71.2) 6.21 (3.02-12.76) 7.18 (3.35-15.36) 
    s1/s2 27 (18.4) 11 (13.8) 2.31 (0.91-5.86) 2.50 (0.96-6.54) 
vacA m genotype     
    m2 83 (56.5) 21 (26.2) 1 [reference] 1 [reference] 
    m1 34 (23.1) 49 (61.3) 5.70 (2.98-10.90) 5.93 (3.02-11.62) 
    m1/m2 30 (20.4) 10 (12.5) 1.32 (0.56-3.12) 1.16 (0.48-2.80) 
Smoking status     
    Never smoker 52 (35.4) 16 (20.0) 1 [reference] 1 [reference] 
    Former smoker 50 (34.0) 28 (35.0) 1.82 (0.88-3.76) 1.78 (0.84-3.76) 
    Current smoker 45 (30.6) 36 (45.0) 2.60 (1.28-5.29) 3.19 (1.51-6.73) 
Tobacco use (pack-years)§     
    Never smoker 52 (36.6) 16 (21.3) 1 [reference] 1 [reference] 
    <20 50 (35.2) 27 (36.0) 1.76 (0.84-3.64) 2.02 (0.95-4.33) 
    ≥20 40 (28.2) 32 (42.7) 2.60 (1.25-5.38) 2.65 (1.26-5.58) 
Alcohol consumption (drinks/wk)     
    ≤1 13 (9.3) 5 (6.8) 1 [reference] 1 [reference] 
    2-6 25 (18.0) 10 (13.5) 1.04 (0.29-3.69) 1.09 (0.30-3.95) 
    ≥7 101 (72.7) 59 (79.7) 1.52 (0.52-4.47) 1.35 (0.45-4.06) 
Wine consumption (drinks/wk)**     
    ≤1 14 (10.3) 6 (8.3) 1 [reference] 1 [reference]†† 
    2-6 27 (19.8) 11 (15.3) 0.95 (0.29-3.11) 0.83 (0.22-3.16) 
    ≥7 95 (69.9) 55 (76.4) 1.35 (0.49-3.72) 1.03 (0.30-3.47) 
Beer consumption (drinks/wk)‡‡     
    ≤1 53 (40.2) 28 (38.9) 1 [reference] 1 [reference]†† 
    2-6 51 (38.6) 34 (47.2) 1.26 (0.67-2.37) 1.56 (0.75-3.25) 
    ≥7 28 (21.2) 10 (13.9) 0.68 (0.29-1.59) 0.64 (0.23-1.78) 
Hard liquor consumption (drinks/wk)§§     
    ≤1 79 (59.0) 48 (64.0) 1 [reference] 1 [reference]†† 
    2-6 50 (37.3) 22 (29.3) 0.72 (0.39-1.34) 0.63 (0.30-1.30) 
    ≥7 5 (3.7) 5 (6.7) 1.64 (0.45-5.98) 2.66 (0.57-12.33) 
*

Age and education adjusted, except if otherwise specified.

Education adjusted.

Age adjusted.

§

Data available for 217 subjects.

Data available for 213 subjects.

Including one never drinker and one ex-drinker.

**

Data available for 208 subjects.

††

Adjusted for age, education, and consumption of other types of alcoholic beverages.

‡‡

Data available for 204 subjects.

§§

Data available for 209 subjects.

The prevalence of infection with high-virulence H. pylori strains was similar among never and ever smokers (35.3% versus 40.9%, P = 0.43). Compared with never smokers infected with low-virulence strains, the risk of intestinal metaplasia was increased 5.7-fold in never smokers infected with high-virulence strains and 3.5-fold in ever smokers with low-virulence infection. Subjects that were simultaneously ever smokers and infected with high-virulence H. pylori strains had the risk of intestinal metaplasia further increased (OR, 8.61; 95% CI, 3.07-24.17; Table 2). No statistically significant interaction was observed in a multiplicative scale (βsmoking × H. pylori virulence = −0.86; P = 0.227) but the interaction contrast ratio was −0.56, not excluding an additive effect.

Table 2.

Association between intestinal metaplasia and H. pylori virulence and smoking status (logistic regression analysis)

Normal stomach/chronic nonatrophic gastritis
Intestinal metaplasia
n (%)n (%)OR (95% CI)*
Never smokers infected with low-virulence H. pylori strains 38 (25.9) 6 (7.5) 1 [reference] 
Never smokers infected with high-virulence H. pylori strains 14 (9.5) 10 (12.5) 5.74 (1.68-19.63) 
Ever smokers infected with low-virulence H. pylori strains 64 (43.5) 30 (37.5) 3.54 (1.30-9.61) 
Ever smokers infected with high-virulence H. pylori strains 31 (21.1) 34 (42.5) 8.61 (3.07-24.17) 
Normal stomach/chronic nonatrophic gastritis
Intestinal metaplasia
n (%)n (%)OR (95% CI)*
Never smokers infected with low-virulence H. pylori strains 38 (25.9) 6 (7.5) 1 [reference] 
Never smokers infected with high-virulence H. pylori strains 14 (9.5) 10 (12.5) 5.74 (1.68-19.63) 
Ever smokers infected with low-virulence H. pylori strains 64 (43.5) 30 (37.5) 3.54 (1.30-9.61) 
Ever smokers infected with high-virulence H. pylori strains 31 (21.1) 34 (42.5) 8.61 (3.07-24.17) 
*

Age and education adjusted.

“High-virulence” means simultaneous infection with cagA+ and vacA s1/m1, vacA s1/m2, or vacA s2/m1; “low-virulence” means otherwise. Subjects simultaneously infected with vacA s1 and s2 strains or vacA m1 and m2 strains were considered as infected with “high-virulence” strains.

As shown in Table 3, infection with high-virulence strains significantly increased the risk of incomplete (OR, 9.81; 95% CI, 2.39-40.31) and mixed (OR, 3.28; 95% CI, 1.51-7.14) intestinal metaplasia. Complete (OR, 2.82; 95% CI, 1.01-7.88) and mixed (OR, 2.97; 95% CI, 1.12-7.84) intestinal metaplasia were more frequent among ever smokers.

Table 3.

Association between complete, incomplete and mixed types of intestinal metaplasia and H. pylori virulence and smoking status (multinomial logistic regression analysis)

Normal stomach/chronic nonatrophic gastritis
Intestinal metaplasia
n (%)Complete
Incomplete
Mixed
n (%)OR (95% CI)*n (%)OR (95% CI)*n (%)OR (95% CI)*
H. pylori infecting strains        
    Low-virulence 102 (69.4) 17 (56.7) 1 [reference] 3 (23.1) 1 [reference] 16 (43.2) 1 [reference] 
    High-virulence 45 (30.6) 13 (43.3) 1.79 (0.79-4.08) 10 (76.9) 9.81 (2.39-40.31) 21 (56.8) 3.28 (1.51-7.14) 
Smoking status        
    Never smoker 52 (35.4) 5 (16.7) 1 [reference] 5 (38.5) 1 [reference] 6 (16.2) 1 [reference] 
    Ever smoker 95 (64.6) 25 (83.3) 2.82 (1.01-7.88) 8 (61.5) 0.86 (0.24-3.02) 31 (83.8) 2.97 (1.12-7.84) 
Normal stomach/chronic nonatrophic gastritis
Intestinal metaplasia
n (%)Complete
Incomplete
Mixed
n (%)OR (95% CI)*n (%)OR (95% CI)*n (%)OR (95% CI)*
H. pylori infecting strains        
    Low-virulence 102 (69.4) 17 (56.7) 1 [reference] 3 (23.1) 1 [reference] 16 (43.2) 1 [reference] 
    High-virulence 45 (30.6) 13 (43.3) 1.79 (0.79-4.08) 10 (76.9) 9.81 (2.39-40.31) 21 (56.8) 3.28 (1.51-7.14) 
Smoking status        
    Never smoker 52 (35.4) 5 (16.7) 1 [reference] 5 (38.5) 1 [reference] 6 (16.2) 1 [reference] 
    Ever smoker 95 (64.6) 25 (83.3) 2.82 (1.01-7.88) 8 (61.5) 0.86 (0.24-3.02) 31 (83.8) 2.97 (1.12-7.84) 
*

Age, education, H. pylori virulence, and smoking status adjusted.

“High-virulence” mean simultaneous infection with cagA+ and vacA s1/m1, vacA s1/m2, or vacA s2/m1; “low-virulence” means otherwise. Subjects simultaneously infected with vacA s1 and s2 strains or vacA m1 and m2 strains were considered as infected with “high-virulence” strains.

The risk of intestinal metaplasia was higher in subjects infected with high-virulence H. pylori strains and among smokers, and was further increased when both factors were simultaneously present. Infection with H. pylori cagA+ and vacA s1/m1 increased the risk of incomplete and mixed intestinal metaplasia, and smoking was associated with a higher frequency of complete and mixed types of intestinal metaplasia.

Our study evaluated male shipyard workers from the northern Portuguese region where the highest incidence of gastric cancer is observed (22), and this precludes the generalization of our observation to low-risk regions. Most subjects in our sample were drinkers, similarly to what is observed in Portugal (only ∼5% of the Portuguese adult males are teetotallers; ref. 23). Therefore, our results about the association between alcohol consumption and intestinal metaplasia are not directly comparable to those obtained in previous studies, which compared drinkers with nondrinkers (10, 11, 13, 24). If an interaction between alcohol consumption and H. pylori infection status is to be considered (25), our conclusions may apply only to populations with a large proportion of drinkers, and not as much to females, which are less likely to consume alcoholic beverages (23).

The results presented in Table 1 suggest that the infection with multiple vacA s strains may be associated with a lower risk of intestinal metaplasia than s1 strains, and these differences are even more pronounced when the infection with multiple vacA m strains is considered. In the analysis presented in Tables 2 and 3, the infection with multiple strains was included in the group defined as “high-virulence,” but the point estimates remained similar in all the analyses done when the subjects infected with multiple strains were excluded (data not shown), even if the association between high-virulence strains and complete intestinal metaplasia became statistically significant, and the study conclusions are not affected by this option.

It was known from previous investigations that both smoking (12-15) and infection with high-virulence H. pylori strains (4-6, 8) increased the risk of intestinal metaplasia. Although our study is not powered enough to detect a subtle interaction as the one that could be anticipated for these exposures, it suggests that the risk of intestinal metaplasia is further increased, in an additive scale, when both smoking and high-virulence H. pylori strains are present.

Our study also adds to prior knowledge the effect of smoking and H. pylori virulence in specific types of intestinal metaplasia, which may contribute to clarify the gastric carcinogenesis pathways. Two interpretative hypotheses seem to be plausible to fit intestinal metaplasia in the carcinogenesis process: (a) the classic sequence (1), where the complete type precedes the incomplete intestinal metaplasia, and (b) an alternative model proposed by Reis et al. (19) in which complete and incomplete intestinal metaplasia represent ab initio divergent differentiation programs. Infection with high-virulence H. pylori strains increases the risk of chronic atrophic gastritis (3, 26-28) and we also observed a clear association with incomplete intestinal metaplasia, but not as strong for the complete type. If atrophy, complete intestinal metaplasia, and incomplete intestinal metaplasia occurred in sequential steps, the association between infection and complete and incomplete intestinal metaplasia would be much more similar because it is not plausible that the observed effects are concealed in these closely related steps.

Most previous investigations did not show an association between smoking and the risk of chronic atrophic gastritis (10, 14, 29-32), but it is clear that cigarette use increases the risk of intestinal metaplasia (all types combined; refs. 10-15, 17, 18). In our study, smoking was significantly associated only with the complete type of intestinal metaplasia. It is plausible that smoking contributes to the progression from chronic atrophic gastritis to complete intestinal metaplasia, but we would not expect a lack of association with the incomplete type if it followed complete intestinal metaplasia because dysplasia (10, 13, 33, 34) and gastric cancer are also associated with smoking (35-37). Therefore, we may hypothesize that smoking acts in the pathways of two different end points: complete intestinal metaplasia (contributing for the progression from chronic atrophic gastritis to complete intestinal metaplasia) and incomplete intestinal metaplasia (contributing for its progression to dysplasia and gastric cancer without influencing the occurrence of incomplete intestinal metaplasia itself).

The risk of the mixed type intestinal metaplasia is increased by both factors considered. Although the magnitude of association for smoking is similar to the one observed with the complete type of intestinal metaplasia, for infection with high-virulence strains, it is intermediate between those observed for the complete and the incomplete types. This could be seen as supportive of model (a), with mixed type intestinal metaplasia being a transition step between complete and incomplete intestinal metaplasia. However, this observation may also fit model (b), with complete and incomplete intestinal metaplasia representing alternative pathways and mixed type intestinal metaplasia being the result of the coexistence of both main types, which may occur in different stomach locations when exposure to both factors occurs simultaneously.

Given the lower frequency of incomplete intestinal metaplasia, our study supports the notion that incomplete intestinal metaplasia is a more serious lesion than complete intestinal metaplasia, regardless of the carcinogenesis model that best fits the observations.

Our results improve our knowledge of gastric carcinogenesis but should be followed by further investigations in larger data sets and including other exposures that potentially modulate the progression of precancerous lesions, such as fruit and vegetables consumption (14, 15, 38-40) and host genetic factors (28, 41-44). In addition, we defined intestinal metaplasia as complete (also designated as type I) and incomplete, although the latter encompasses both types II and III (with different patterns of mucins expression; ref. 45). When all these three subtypes are considered, an alternative model for intestinal metaplasia progression may be taken into account (19), with type II intestinal metaplasia representing the first step in the intestinal metaplasia pathway, which may evolve to type I or type III intestinal metaplasia. Our results do not exclude this hypothesis, but reclassification of the incomplete intestinal metaplasia cases would be necessary to allow a further insight on this topic.

In conclusion, our study confirms that infection with high-virulence H. pylori strains and smoking increase the risk of intestinal metaplasia. It also shows that these factors are differentially associated with the complete and incomplete types of intestinal metaplasia, suggesting divergent pathways in gastric carcinogenesis.

This work was performed using grants from the Fundação Calouste Gulbenkian (projects FC-54918 and FC-68697).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1
Correa P, Haenszel W, Cuello C, Tannenbaum S, Archer M. A model for gastric cancer epidemiology.
Lancet
1975
;
2
:
58
–60.
2
Warburton VJ, Everett S, Mapstone NP, Axon AT, Hawkey P, Dixon MF. Clinical and histological associations of cagA and vacA genotypes in Helicobacter pylori gastritis.
J Clin Pathol
1998
;
51
:
55
–61.
3
Nogueira C, Figueiredo C, Carneiro F, et al. Helicobacter pylori genotypes may determine gastric histopathology.
Am J Pathol
2001
;
158
:
647
–54.
4
Prinz C, Schoniger M, Rad R, et al. Key importance of the Helicobacter pylori adherence factor blood group antigen binding adhesin during chronic gastric inflammation.
Cancer Res
2001
;
61
:
1903
–9.
5
Yamaoka Y, Kikuchi S, el-Zimaity HM, Gutierrez O, Osato MS, Graham DY. Importance of Helicobacter pylori oipA in clinical presentation, gastric inflammation, and mucosal interleukin 8 production.
Gastroenterology
2002
;
123
:
414
–24.
6
Yu J, Leung WK, Go MY, et al. Relationship between Helicobacter pylori babA2 status with gastric epithelial cell turnover and premalignant gastric lesions.
Gut
2002
;
51
:
480
–4.
7
Gallo N, Zambon CF, Navaglia F, et al. Helicobacter pylori infection in children and adults: a single pathogen but a different pathology.
Helicobacter
2003
;
8
:
21
–8.
8
Zambon CF, Navaglia F, Basso D, Rugge M, Plebani M. Helicobacter pylori babA2, cagA, and s1 vacA genes work synergistically in causing intestinal metaplasia.
J Clin Pathol
2003
;
56
:
287
–91.
9
Mesquita P, Almeida R, Lunet N, et al. Metaplasia—a transdifferentiation process that facilitates cancer development. The model of gastric intestinal metaplasia.
Crit Rev Oncog
2006
;
12
:
1
–24.
10
Kato I, Vivas J, Plummer M, et al. Environmental factors in Helicobacter pylori-related gastric precancerous lesions in Venezuela.
Cancer Epidemiol Biomarkers Prev
2004
;
13
:
468
–76.
11
Shousha S, Barrison IG, El-Sayeed W, Khan S, Parkins RA. A study of incidence and relationship of intestinal metaplasia of gastric antrum and gastric metaplasia of duodenum in patients with nonulcer dyspepsia.
Dig Dis Sci
1984
;
29
:
311
–6.
12
Tatsuta M, Iishi H, Okuda S. Effect of cigarette smoking on extent of acid-secreting area and intestinal metaplasia in the stomach.
Dig Dis Sci
1988
;
33
:
23
–9.
13
Kneller RW, You WC, Chang YS, et al. Cigarette smoking and other risk factors for progression of precancerous stomach lesions.
J Natl Cancer Inst
1992
;
84
:
1261
–6.
14
Jedrychowski W, Popiela T, Drews M, et al. Effect of Helicobacter pylori infection, smoking and dietary habits on the occurrence of antrum intestinal metaplasia. Clinico-epidemiological study in Poland.
Pol J Pathol
1999
;
50
:
289
–95.
15
Russo A, Maconi G, Spinelli P, et al. Effect of lifestyle, smoking, and diet on development of intestinal metaplasia in H. pylori-positive subjects.
Am J Gastroenterol
2001
;
96
:
1402
–8.
16
Nakamura M, Haruma K, Kamada T, et al. Cigarette smoking promotes atrophic gastritis in Helicobacter pylori-positive subjects.
Dig Dis Sci
2002
;
47
:
675
–81.
17
Leung WK, Lin SR, Ching JY, et al. Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication.
Gut
2004
;
53
:
1244
–9.
18
Stemmermann GN, Nomura AM, Chyou PH, Hankin J. Impact of diet and smoking on risk of developing intestinal metaplasia of the stomach.
Dig Dis Sci
1990
;
35
:
433
–8.
19
Reis CA, David L, Correa P, et al. Intestinal metaplasia of human stomach displays distinct patterns of mucin (MUC1, MUC2, MUC5AC, and MUC6) expression.
Cancer Res
1999
;
59
:
1003
–7.
20
van Doorn LJ, Figueiredo C, Rossau R, et al. Typing of Helicobacter pylori vacA gene and detection of cagA gene by PCR and reverse hybridization.
J Clin Microbiol
1998
;
36
:
1271
–6.
21
Kalilani L, Atashili J. Measuring additive interaction using odds ratios.
Epidemiol Perspect Innov
2006
;
3
:
5
.
22
Lunet N, Pina F, Barros H. Regional trends in Portuguese gastric cancer mortality (1984-1999).
Eur J Cancer Prev
2004
;
13
:
271
–5.
23
Santos AC, Lopes C, Guimaraes JT, Barros H. Central obesity as a major determinant of increased high-sensitivity C-reactive protein in metabolic syndrome.
Int J Obes (Lond)
2005
;
29
:
1452
–6.
24
Nomura A, Yamakawa H, Ishidate T, et al. Intestinal metaplasia in Japan: association with diet.
J Natl Cancer Inst
1982
;
68
:
401
–5.
25
Lunet N, Barros H. Helicobacter pylori infection and gastric cancer: facing the enigmas.
Int J Cancer
2003
;
106
:
953
–60.
26
Ando T, Goto Y, Maeda O, Watanabe O, Ishiguro K, Goto H. Causal role of Helicobacter pylori infection in gastric cancer.
World J Gastroenterol
2006
;
12
:
181
–6.
27
Matysiak-Budnik T, Megraud F. Helicobacter pylori infection and gastric cancer.
Eur J Cancer
2006
;
42
:
708
–16.
28
Figueiredo C, Machado JC, Pharoah P, et al. Helicobacter pylori and interleukin 1 genotyping: an opportunity to identify high-risk individuals for gastric carcinoma.
J Natl Cancer Inst
2002
;
94
:
1680
–7.
29
Namekata T, Miki K, Kimmey M, et al. Chronic atrophic gastritis and Helicobacter pylori infection among Japanese Americans in Seattle.
Am J Epidemiol
2000
;
151
:
820
–30.
30
Ito LS, Oba-Shinjo SM, Marie SK, et al. Lifestyle factors associated with atrophic gastritis among Helicobacter pylori-seropositive Japanese-Brazilians in Sao Paulo.
Int J Clin Oncol
2003
;
8
:
362
–8.
31
Ozasa K, Kurata JH, Higashi A, et al. Helicobacter pylori infection and atrophic gastritis: a nested case-control study in a rural town in Japan.
Dig Dis Sci
1999
;
44
:
253
–6.
32
Kuwahara Y, Kono S, Eguchi H, Hamada H, Shinchi K, Imanishi K. Relationship between serologically diagnosed chronic atrophic gastritis, Helicobacter pylori, and environmental factors in Japanese men.
Scand J Gastroenterol
2000
;
35
:
476
–81.
33
Dobrilla G, Benvenuti S, Amplatz S, Zancanella L. Chronic gastritis, intestinal metaplasia, dysplasia and Helicobacter pylori in gastric cancer: putting the pieces together.
Ital J Gastroenterol
1994
;
26
:
449
–58.
34
You WC, Li JY, Zhang L, et al. Etiology and prevention of gastric cancer: a population study in a high risk area of China.
Chin J Dig Dis
2005
;
6
:
149
–54.
35
Tredaniel J, Boffetta P, Buiatti E, Saracci R, Hirsch A. Tobacco smoking and gastric cancer: review and meta-analysis.
Int J Cancer
1997
;
72
:
565
–73.
36
Gonzalez CA, Pera G, Agudo A, et al. Smoking and the risk of gastric cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC).
Int J Cancer
2003
;
107
:
629
–34.
37
Chao A, Thun MJ, Henley SJ, Jacobs EJ, McCullough ML, Calle EE. Cigarette smoking, use of other tobacco products and stomach cancer mortality in US adults: The Cancer Prevention Study II.
Int J Cancer
2002
;
101
:
380
–9.
38
Judd PA. Diet and precancerous lesions of the stomach.
Eur J Cancer Prev
1993
;
2
:
65
–71.
39
Malekzadeh R, Sotoudeh M, Derakhshan MH, et al. Prevalence of gastric precancerous lesions in Ardabil, a high incidence province for gastric adenocarcinoma in the northwest of Iran.
J Clin Pathol
2004
;
57
:
37
–42.
40
Zhang L, Blot WJ, You WC, et al. Serum micronutrients in relation to pre-cancerous gastric lesions.
Int J Cancer
1994
;
56
:
650
–4.
41
El-Omar EM, Carrington M, Chow WH, et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer.
Nature
2000
;
404
:
398
–402.
42
Furuta T, El-Omar EM, Xiao F, Shirai N, Takashima M, Sugimura H. Interleukin 1β polymorphisms increase risk of hypochlorhydria and atrophic gastritis and reduce risk of duodenal ulcer recurrence in Japan.
Gastroenterology
2002
;
123
:
92
–105.
43
Machado JC, Figueiredo C, Canedo P, et al. A proinflammatory genetic profile increases the risk for chronic atrophic gastritis and gastric carcinoma.
Gastroenterology
2003
;
125
:
364
–71.
44
Leung WK, Chan MC, To KF, et al. H. pylori genotypes and cytokine gene polymorphisms influence the development of gastric intestinal metaplasia in a Chinese population.
Am J Gastroenterol
2006
;
101
:
714
–20.
45
Filipe MI, Jass JR. Intestinal metaplasia subtypes and cancer risk. In: Filipe MI, Jass JR, editors. Gastric carcinoma. London: Churchill Livingstone; 1986. p. 87–115.